inhibitors such as cPLA2, COX-2 and dual inhibitors 4, 7 (lipoxygenase and COX) could not only teach us more about the checkpoints in the innate recognition system that are amenable to a small molecule approach, but also about new therapeutic tools to treat ARDS that may prove relevant to related disorders. Further studies with these cPLA2 -/-mice will permit the assessment of selectivity of cPLA2-directed treatments as well as help define the scope of new therapies for ARDS.
There are two situations in which, at least theoretically, dysregulation of normal cellular turnover can have catastrophic consequences for the individual. One of these, of course, is cancer, and it is for this reason that each cell has a variety of intracellular 'checks' and 'suppressors' to ensure that cellular proliferation proceeds in a controlled and regulated manner. The other is as a consequence of autoimmunity. This situation arises when a T cell, which is normally activated to proliferate and eliminate foreign antigen, instead is activated in response to a "self" protein and launches a destructive immune response against the tissues in the body that express this particular antigen. In this issue, Hakem et al. investigate how a tumor suppressor, Brca1, controls the life and death of T lymphocytes Without Brca1,T cells are lacking in numbers and maturity, but surprisingly not because of a lack of repair of rearranged TCR genes.The defects involve more than one p53-dependent mechanism.
ceed through a series of trials designed to ensure that those clones guilty of the capacity to initiate an autoimmune catastrophe are punished by death. It is thought that autoimmunity manifests when such "forbidden clones" escape the death sentence and instead survive to initiate their path of destruction. Precursors of T cells arise in the bone marrow and then make their way to the thymus where their maturation and trials commence. During the next few days the cell rearranges the segments of its T cell receptor (TCR) genes, a process which requires effective DNA repair and expression of the TCR proteins (first trial).
The T cell receptor protein must react with ligands (major histocompatibility molecules bearing antigenic peptides in the thymus, usually derived from self proteins) with an intermediate affinity-one high enough to ensure the signaling required to maintain the cell's survival (second trial) but below the threshold necessary for induction of an activation-induced apoptotic pathway (third trial). Failure in any of these trials ensures an automatic death penalty.
These trials ensure that maturing T cells can generate effective immune responses without inadvertantly responding to peptides from self pro- 
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teins and launching an autoimmune attack. But for this to work properly, the cell must be insulated against spontaneous mutations in the T cell receptor genes that might undermine the value of these stringent tests. We know that it need not take much to change an antigen receptor to a "self-antigen" receptor-in antibodies, a single base change can have this effect. The system ensures against this in two ways: efficient DNA repair mechanisms function prior to the critical trials (especially the third trial), and sensors that detect DNA breaks trigger death of the cell, rather than risk the consequence of emergence of a forbidden clone. DNA repair mechanisms are needed in any case for sealing the breaks produced during the rearrangement of the T cell receptor gene segments, as also are pathways into apoptotic death (for any cell that fails any of its trials, see Fig. 1 ). Therefore, we might have expected that the repair mechanisms involved in sealing the coding joints of the T cell receptor genes and those involved in the repair of environmentally induced DNA damage would be the same. It appears that we would have been wrong.
On -/-or a transgenic Bcl-2-overexpressing background, but not by a p21 -/-background, providing evidence for p53-dependent apoptosis as the mechanism for thymocyte loss. The surviving thymocytes express TCR, indicating that Brca1 is not required for the repair of the rearranged genes. Why, then, does its absence consign the developing T cells to death?
The human BRCA1 locus encodes a large, 1863-amino-acid protein, which is frequently mutated in familial breast and ovarian cancer. Brca1 is detected in discrete nuclear foci, and upon radiation-induced DNA damage it colocalizes with the repair proteins hRad50, hMre11 and p95/Nbs1 (ref. 2). Furthermore, it also complexes with the repair gene hRAD51 via binding to Brca2 (ref.
3). Targeted disruption of Brca1 in the mouse leads to early embryonic lethality, which resembles the phenotype of Rad51 -/-mice, arguing for a role in cell proliferation and repair 4 . The defect in thymocyte development unraveled by the analysis of tBrca1 -/-mice is partially reminiscent of the scid phenotype observed following functional loss of the components of the DNA-PK (Ku70, Ku80 and DNA-PKcs), which results in an arrest of thymocyte development at the DN stage due to the inability to join coding ends, a crucial step of TCR rearrangement. Unlike in tBrca1 -/-animals, however, Bcl-2 does not rescue scid thymocytes 5 , although the absence of p53 allows some maturation to the DP stage 6 . Clearly, the requirements for DNA-PK and for Brca1 are different, and defects in these two repair proteins have fundamentally different consequences.
So why is there still this massive thymocyte apoptosis in tBrca1 -/-animals? There are two possible explanations, one being that the DNA-PK complex is necessary but not sufficient to repair the RAG-1-and RAG-2-induced DNA double strand breaks occuring during V(D)J recombination. This is supported by the ability of functionally rearranged TCR to completely restore lymphocyte development in RAG-1-or RAG-2-deficient mice 7, 8 , but not in scid mice 9 . Thus, Brca1 in complex with Rad50 and Rad51 might be required for successful repair of the DNA damage occuring during V(D)J recombination. This, however, doesn't jibe with the successful expression of TCR on the Brca1 -/-T cells, rescued by Bcl-2 or by the absence of p53, as noted by Hakem et al. 1 . Alternatively, DNA damage, normally repaired by Brca1, leads to p53 activation and apoptosis in the thymocytes, and this is not due to the TCR rearrangement process per se. Then what is responsible for this DNA damage? Do all cells harbor such instability or is there something inherently damaging about the lifestyle of an immature thymocyte? Proliferating mature T cells appear to generate high levels of reactive oxygen species 10 and it is possible that proliferating DN thymocytes are faced with a similar damaging situation. Repair by Brca1 may therefore be necessary to prevent p53-mediated, Bcl-2 inhibitable death in the ubiquitously damaged thymocytes.
The role of p53 in each case (scid versus tBrca1 -/-) may also be different. Bcl-2 rescues Brca1 -/-thymocytes but cannot rescue those with the scid defect 5 . As most apoptotic pathways are blocked by Bcl-2, this suggests either that the p53-mediated developmental block in developing T cells lacking rearranged T cell receptor genes is due to cell cycle arrest rather than death (and p53-induced cell cycle arrest is not inhibited by Bcl-2) or that in this particular case p53 induces death via a Bcl-2 insensitive pathway. For a few reasons, the latter is conceivable (if not very likely). First, p53 can trigger cell death through Fas (CD95) expression 11 . Second Fas-deficient, scid thymocytes can develop 12 . And finally, Bcl-2 fails to block Fas-mediated apoptosis in the thymus 13 . Therefore, there may be two p53 checkpoints, one of which leads to Bcl-2 inhibitable death, and a second that stops T cell development (whether via death or developmental arrest) in a Bcl-2 independent manner (see Fig. 1) . Support for such a p53-dependent monitor on cell-surface TCR expression is provided by the observation that CD3γ-deficient T cells develop in p53 -/-but not wild-type or Bcl-2 overexpressing thymuses 14 . Effects on peripheral T cells in tBrca1 the other molecules in Fig. 2 and their relationships to the proposed checkpoints in Fig. 1 will come with complementation studies using these knockout mice.
In the absence of Brca1 and p53-mediated arrest and apoptosis, the surviving T cells show extensive chromosomal abnormalities 1 . If this is indicative of a general genomic instability, then it is possible that mutations in the TCR, following successful completion of all trials by the developing cell, might convert some of these into "forbidden clones," capable of responding to autologous tissue proteins. If so, then these animals lacking T cell Brca1 and p53 may become autoimmune. That is, of course, if cancer doesn't kill them first. mice are also informative. These cells are largely missing, and the Bcl-2-overexpressing background did not rescue this defect, whereas a p53 -/-background, or a p21 -/-background did so partially. This might result from a DNA damage response in peripheral T cells favoring a p53-dependent, p21-dependent cell cycle arrest at the G1 checkpoint. Moreover, the apoptotic response of peripheral T cells might be triggered by death receptor pathways (such as Fas), which can proceed in the presence of ectopic Bcl-2 expression 13 . The DNA damage pathways that engage p53, cell cycle arrest and apoptosis, and the roles of the associated molecules in thymocytes, as determined in knock-out studies, are shown in Fig. 2 . In response to DNA damage, p53 is most likely activated in an Atm-dependent manner, which could be further studied by crossing the tBrca1 -/-mice to an Atm 2, 3 . Importantly, these questions and the elucidation of the exact molecular mechanisms of the immunoregulatory actions of type 1 IFNs are not merely of academic interest. On the contrary, these issues could have therapeutic implications. For example, IFN-β is empirically used in the treatment of multiple sclerosis (MS) but exactly how and why it works is unclear.
Although the antiviral function of type 1 IFNs is well established, a controversial and confusing issue has been their role in helper T cell development and the regulation of IFN-γ production (it should be noted that IFN-γ is also termed type 2 IFN). A fundamentally important aspect of immune responses is the control of helper T cell differentiation into subsets that predominantly produce either IFN-γ and lymphotoxin (the T helper 1 or TH1 subset) or interleukin 4 (IL-4) and other cytokines (TH2 subset) 4 . It is now clear that the differentiation of TH1 cells is crucial for an effective host response to intracellular parasites but this subset is also thought to contribute to the pathogenesis of a variety of autoimmune disorders such as rheumatoid arthritis, Crohn's disease and multiple sclerosis (MS). TH1 differentiation and IFN-γ production is positively regulated by the cytokine IL-12. The importance of IL-12 is vividly
